Oxford, England, and Madison, New Jersey, October 30, 2025 — Terumo Corporation, a global leader in medical technology, has officially completed its acquisition of OrganOx Limited, a UK-based pioneer in normothermic machine perfusion (NMP) systems used for organ preservation and transplantation. The transaction marks Terumo’s formal expansion into the organ-transplantation sector and positions the company to advance the global standard of organ preservation, perfusion, and clinical transplantation support. OrganOx, a spin-out from the University of Oxford, will operate as a wholly owned subsidiary within Terumo’s global portfolio, maintaining its operational base in the UK.
Science Significance
The acquisition unites two world-class medical-device innovators focused on improving transplant outcomes through science and engineering. OrganOx’s flagship product, the metra® NMP device, enables liver preservation at near-body temperature by continuously perfusing oxygenated blood and nutrients, thereby maintaining the organ’s natural metabolism and allowing viability assessment before transplantation. This represents a paradigm shift from conventional cold-storage methods, which can degrade tissue integrity. By leveraging Terumo’s R&D and manufacturing resources, the acquisition will accelerate next-generation organ-perfusion systems and potentially expand into kidney, heart, and lung applications — solidifying a new scientific frontier in transplant-biomedical innovation.
Regulatory Significance
From a regulatory perspective, the transaction reinforces Terumo’s commitment to cGxP-aligned manufacturing and post-market quality systems. OrganOx’s metra® device holds U.S. FDA approval, CE mark, and UKCA certification, underscoring its global compliance readiness. The integration under Terumo’s corporate governance and international regulatory infrastructure ensures adherence to ISO 13485, MDSAP, and regional device-safety frameworks. Moreover, as regulatory authorities increasingly emphasize evidence-based medical-device validation and patient-safety outcomes, this merger exemplifies how strategic collaborations can meet both scientific and regulatory rigor in life-saving device innovation.
Business Significance
Advertisement
For Terumo, the acquisition represents a strategic milestone worth approximately USD 1.5 billion, aligning with its long-term plan to diversify into high-value medtech segments beyond cardiovascular and blood-management technologies. The deal provides access to OrganOx’s clinical network spanning more than 30 countries and over 6,000 successful liver perfusions, giving Terumo an immediate foothold in the transplant-device market projected to exceed USD 3 billion by 2030. For OrganOx, joining Terumo’s global supply chain unlocks large-scale manufacturing capabilities, cross-border logistics, and financial resources needed to expand commercial adoption of machine-perfusion technology across major transplant centers.
Patients’ Significance
For transplant patients, this acquisition has the potential to dramatically improve organ-transplant success rates and expand the donor-organ pool. The metra® system allows surgeons to evaluate organ viability in real time, enabling the use of organs previously considered marginal. Clinical evidence shows that normothermic perfusion reduces organ failure rates, extends preservation times up to 24 hours, and improves post-transplant recovery outcomes. By combining Terumo’s global reach with OrganOx’s breakthrough technology, patients worldwide could benefit from shorter waiting times, better graft survival, and improved quality of life following transplantation.
Policy Significance
This acquisition aligns with global health policies promoting innovation in organ transplantation and equitable access to life-saving procedures. Regulatory bodies in Europe, the U.S., and Asia have increasingly encouraged the adoption of advanced organ-preservation technologies to address donor shortages. The transaction also supports national policy goals for sustainable healthcare innovation, as it integrates academic discovery with commercial scale-up. Through this acquisition, Terumo reinforces international collaboration in One-Health and life-sciences innovation policy, bridging research translation, patient safety, and ethical medical advancement.
The completion of Terumo’s acquisition of OrganOx marks a turning point in the evolution of organ-preservation science and global medtech leadership. By merging OrganOx’s precision perfusion technology with Terumo’s international expertise in regulated medical-device development, the partnership embodies the convergence of science, compliance, and compassion. This transaction not only extends Terumo’s innovation footprint but also advances the future of transplant medicine — transforming how donor organs are preserved, assessed, and ultimately used to save lives across continents.
Source: OrganOx Limited. press release
